An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype

Journal of Pharmaceutical and Biomedical Analysis

Volumn 86, Issue , 2013, Pages 73-81

  Wu, Yuling ^a   Liu, Xu ^a   Chen, Yan ^a   Woods, Robert ^a   Lee, Nancy ^a   Yang, Harry ^a   Chowdhury, Partha ^a   Roskos, Lorin K ^a   White, Wendy I ^a  

^a MEDIMMUNE   (United States)

Author keywords

ADA; Chimeric antibody; Hypersensitivity; IgE; Immunoassay

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN E; OMALIZUMAB; RUTHENIUM;

ACCURACY; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; ELECTRON CAPTURE DETECTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; VALIDATION PROCESS;

ADA; CHIMERIC ANTIBODY; HYPERSENSITIVITY; IGE; IMMUNOASSAY;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ELECTROCHEMICAL TECHNIQUES; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE;

EID: 84883137036     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.06.005     Document Type: Article

References (32)

1. Reichert J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 2008, 9:423-430.
2. Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., Bao W., Fowler-Taylor A., Matthews J., Busse W.W., Holgate S.T., Fahy J.V. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 2004, 170:583-593.
3. Eugen K., Holly W.S., Elizabeth S., Gopi S. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1-9.
4. Swanson S.J. Immunogenecity issues in drug development. J. Immunotoxicil. 2006, 3:165-172.
5. Svenson M., Geborek P., Saxne T., Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007, 46:1828-1834.
6. Vultaggio A., Maggi E., Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr. Opin. Allergy Clin. Immunol. 2011, 11:262-268.
7. Marc D., Olson K. Hypersensitivity Reactions and Detection Methods 2009, NeuroScience, Inc.
8. Sicherer S.H., Leung D.Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009. J. Allergy Clin. Immunol. 2010, 125:85-97.
9. Yamasaki S., Saito T. Regulation of mast cell activation through FcepsilonRI. Chem. Immunol. Allergy 2005, 87:22-31.
10. Stubenrauch K., Wessels U., Birnboeck H., Ramirez F., Jahreis A., Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin. Ther. 2010, 32:1597-1609.
11. Timm V., Gruber P., Wasiliu M., Lindhofer H., Chelius D. Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:777-784.
12. Muñoz-Cano R., Carnés J., Sanchez-Lopez J., Saiz A., Bartra J., Lopez-Matas M.A., Picado C., Valero A. Biological agents: new drugs, old problems. J. Allergy Clin. Immunol. 2010, 126:394-395.
13. Georgitis J.W., Browning M.C., Steiner D., Lorentz W.B. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann. Allergy 1991, 66:343-347.
14. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., Slebos R.J., Zhou Q., Gold D., Hatley T., Hicklin D.J., Platts-Mills T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 358:1109-1117.
15. Rajan T.V. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003, 7:376-379.
16. Pascual C., Crespo J.F., Quiralte J., Lopez C., Wheeler G., Martin-Esteban M.l. In vitro detection of specific IgE antibodies to erythromycin. J. Allergy Clin. Immunol. 1995, 95:668-671.
17. Gleich G.J., Jones R.T. Measurement of IgE antibodies by the radioallergosorbent test, I. Technical considerations in the performance of the test. J. Allergy Clin. Immunol. 1975, 55:334-345.
18. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., Romagnani S., Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
19. Erwin E.A., Custis N.J., Satinover S.M., Perzanowski M.S., Woodfolk J.A., Crane J., Wickens K., Platts-Mills T.A. Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase. J. Allergy Clin. Immunol. 2005, 115:1029-1035.
20. ® system in Korean allergy patients. Clin. Chim. Acta 2012, 413:914-919.
21. Design and validation of immunoassays for assessment of human allergenicity of new biotherapeutics drugs: approved guideline. Clin. and Lab. Standards Inst. I/LA34-A, vol. 31, no. 12.
22. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit. 1999, 12:279-284.
23. Beck A., Haeuw J.F., Wurch T., Goetsch L., Bailly C., Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov. Med. 2010, 10:329-339.
24. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev. Clin. Immunol. 2011, 7:55-63.
25. Brennan P.J., Rodriguez Bouza T., Hsu F.I., Sloane D.E., Castells M.C. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J. Allergy Clin. Immunol. 2009, 124:1259-1266.
26. Vogel W.H. Infusion reactions: diagnosis, assessment, and management. Clin. J. Oncol. Nurs. 2010, 14:10-21.
27. Wu Y.L., Lee J.W., Uy L., Abosaleem B., Gunn H., Ma M., DeSilva B. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J. Pharm. Biomed. Anal. 2009, 49:1203-1212.
28. Zhong Z.D., Dinnogen S., Hokom M., Ray C., Weinreich D., Swanson S.J., Chirmule N. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 2010, 355:21-28.
29. Woodfolk J.A. A new paradigm for immunoglobulin E in allergic diseases. Curr. Allergy Asthma Rep. 2005, 5:227-232.
30. Achatz G., Achatz-Straussberger G., Feichtner S., Koenigsberger S., Lenz S., Peckl-Schmid D., Zaborsky N., Lamers M. The biology of IgE: molecular mechanism restraining potentially dangerous high serum IgE titres in vivo. Cancer and IgE, Introducing the Concept of AllergoOncology 2010, 13-36. M.L. Penichet, E. Jensen-Jarolim (Eds.).
31. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
32. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.